Benzinga · Feb 23, 2026
HC Wainwright & Co. Reiterates Buy on Fortress Biotech, Maintains $17 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Fortress Biotech (NASDAQ:FBIO) with a Buy and maintains $17 price target.
FB
NASDAQ · FBIO
Fortress Biotech, Inc.
Healthcare · Biotechnology
$2.05
Down-$0.04 (-1.91%)
Updated Oct 7, 2026, 3:44 AM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 90.78M
- P/E ratio
- 11.44
- Dividend yield
- 0.00%
- 52-week range
- $2.00 – $3.84
- Volume
- 223.99K
- Avg. volume
- 760.74K
Price performance · FBIO
FBIO price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
FBIO closed at $2.05 after 21 trading sessions, down 24.35% for the selected period.
- Last close
- $2.05
- Period change
- -24.35%
- Period low
- $2.03
- Period high
- $2.71
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $2.09 | $2.1317 | $2.02 | $2.05 | 223.99K |
| Oct 5, 2026 | $2.03 | $2.135 | $2.00 | $2.09 | 553.82K |
| Oct 2, 2026 | $2.08 | $2.09 | $2.01 | $2.03 | 327.17K |
| Oct 1, 2026 | $2.17 | $2.17 | $2.07 | $2.07 | 286.25K |
| Sep 30, 2026 | $2.20 | $2.20 | $2.14 | $2.14 | 221.33K |
| Sep 29, 2026 | $2.20 | $2.21 | $2.14 | $2.20 | 257.17K |
| Sep 28, 2026 | $2.26 | $2.2699 | $2.17 | $2.17 | 263.26K |
| Sep 25, 2026 | $2.27 | $2.32 | $2.26 | $2.28 | 264.89K |
| Sep 24, 2026 | $2.33 | $2.345 | $2.28 | $2.28 | 203.68K |
| Sep 23, 2026 | $2.445 | $2.445 | $2.33 | $2.34 | 331.82K |
| Sep 22, 2026 | $2.42 | $2.47 | $2.40 | $2.45 | 199.73K |
| Sep 21, 2026 | $2.50 | $2.52 | $2.39 | $2.41 | 283.34K |
| Sep 18, 2026 | $2.50 | $2.565 | $2.47 | $2.51 | 414.78K |
| Sep 17, 2026 | $2.49 | $2.51 | $2.44 | $2.51 | 167.54K |
| Sep 16, 2026 | $2.48 | $2.505 | $2.41 | $2.46 | 352.89K |
| Sep 15, 2026 | $2.51 | $2.5299 | $2.46 | $2.49 | 225.32K |
| Sep 14, 2026 | $2.50 | $2.54 | $2.46 | $2.53 | 226.48K |
| Sep 11, 2026 | $2.59 | $2.6246 | $2.52 | $2.52 | 209.7K |
| Sep 10, 2026 | $2.60 | $2.625 | $2.53 | $2.57 | 315.55K |
| Sep 9, 2026 | $2.67 | $2.70 | $2.62 | $2.63 | 280.4K |
| Sep 8, 2026 | $2.69 | $2.75 | $2.67 | $2.71 | 263.05K |
Latest FBIO news
The latest Smart Investors Daily articles mentioning FBIO.
Stock researchCompany · Overview
Company
Market Activity
Research & News
FBIO research
Overview
Company profile and research snapshot.
Company profile
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $10.97
- Implied upside
- —
- Analysts
- 8
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 23, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 21, 2025 | HC Wainwright & Co. | Buy | — |
| Mar 11, 2025 | Roth MKM | Buy | — |
| Nov 18, 2024 | HC Wainwright & Co. | Buy | — |
| Jul 19, 2024 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 23, 2026
Fortress Biotech Subsidiary Cyprium Therapeutics To Sell Rare Pediatric Disease Priority Review Voucher For $205M
SeekingAlpha · Feb 19, 2026
Fortress Biotech: The PRV Catalyst That Could Reprice This Microcap
globenewswire.com · Dec 10, 2025
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
Clinical trial achieved all three primary objectives with no significant safety issues being reported Results indicate that Emrosi can be safely used for up to 16 weeks with no detectable impact on skin, GI tract or vaginal microbiota FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions of rosacea in adults SCOTTSDALE, Ariz., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that results from the Phase 1 clinical trial (DFD-29-CD-006) assessing the impact of low-dose oral minocycline (“DFD-29” or commercially known as “Emrosi™) on skin, gastrointestinal (“GI”) and vaginal microflora in healthy adults were published in the Journal of Drugs in Dermatology, a leading peer-reviewed publication in clinical dermatology.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
